RAF1 and RASopathy: Thus, the RASopathy-derived mutations constitutively, but moderately, activate MEK1 in a manner independent of T-loop phosphorylation, whereas the cancer-derived mutations markedly augment MEK1 activity through the T-loop phosphorylation by a Raf-independent mechanism.